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Takedatsu et al.1 in their article titled “A new therapeutic 
approach using a schizophyllan-based drug delivery system 
for inflammatory bowel disease” recently reported a novel 
therapeutic approach for inflammatory bowel disease using 
an innovative delivery system for antisense oligonucleotides 
(ODNs) that is based on Schizophyllan (SPG), a polysaccha-
ride that belongs to the β-(1-3) glucan family.1 These authors 
demonstrated that this system has several advantages over 
the effective suppression of targeted RNA. The SPG com-
plex is stable in vivo and is not a substrate for deoxyribonu-
clease; furthermore, it is efficiently taken up by macrophages 
through the dectin-1 receptor. In particular, Takedatsu et al.1 
administered an antisense migration inhibitory factor/SPG 
complex that significantly ameliorated intestinal inflammation 
in a mouse model.1
The development of this new delivery system is very impor-
tant because therapeutic applications of antisense ODNs 
have recently been shown to be effective against many differ-
ent types of disease, including inflammatory, oncological, and 
genetic disorders. In particular, the use of antisense ODNs 
exploiting antisense-mediated exon skipping, has been suc-
cessfully developed to modulate splicing of the dystrophin 
gene in Duchenne muscular dystrophy.2
Here, we utilized SPG to inhibit the lectin-like oxidized low-
density lipoprotein (LDL) receptor 1 (LOX-1) gene in vivo as 
a possible treatment for atherosclerosis.
LOX-1, which is encoded by the oxidized LDL receptor 1 
(OLR1) gene,3 is the major receptor for ox-LDL in endothelial 
cells. As such, LOX-1 is responsible for the binding, uptake, 
and degradation of oxLDLs.4 LOX-1 is also expressed in 
macrophages, vascular smooth muscle cells, platelets, and 
cardiomyocytes.4 Multiple lines of evidence have implicated 
LOX-1 in the pathogenesis of atherosclerosis,5 and LOX-1 
has emerged as a promising therapeutic target for athero-
sclerosis and related diseases within the last several years.6
Specific antisense ODNs targeting LOX-1 mRNA have 
previously been used for in vitro experiments to study the 
pathophysiological relevance of LOX-1.7 Here, we extend 
these findings, showing for the first time that LOX-1 antisense 
ODNs are effective as a therapeutic strategy in vivo.
In collaboration with NapaJen (NapaJen Pharma, Koganei, 
Japan) and as described by Takedatsu et al.,1 we created a 
new SPG complex consisting of an antisense phosphorothio-
ate ODN targeting the coding sequence (exon 7) of the murine 
Olr1 mRNA and two single SPG chains (SPG/Olr1AS).
The inhibitory effect of the SPG/Olr1AS complex was first 
assessed in vitro in RAW 264.7 murine macrophages. RAW 
264.7 cells were transfected with increasing concentrations 
of SPG/Olr1AS complex (from 25 to 800 nmol/l) or a scram-
ble control ODN/SPG complex (SPG/CTRL). At 24 hours 
after transfection, RNA and proteins were extracted, and 
LOX-1 expression was assessed. We observed a decrease 
in LOX-1 mRNA and protein levels at all SPG/Olr1AS con-
centrations tested, but LOX-1 downregulation was most 
significant at 25 nmol/l SPG/Olr1AS (P < 0.05) (Figure 1). 
At this concentration, mRNA and protein expression levels 
were reduced to ~60 and 80%, respectively, compared with 
nontransfected cells. Notably, the SPG/CTRL complex had 
no effect (Figure 1).
These in vitro data, demonstrating that even the lowest 
concentration of SPG/Olr1AS tested was able to inhibit the 
expression of the LOX-1 receptor, prompted us to investigate 
its activity in vivo in a mouse model of atherosclerosis, the 
apolipoprotein E knock out (ApoE−/−) mouse. We evaluated 
the efficacy of two different doses of the SPG complex (0.05 
and 0.005 mg/kg body weight); both dosages were lower 
than those used for inflammatory bowel disease.1 This inves-
tigation conformed to the European Commission Directive 
86/609/EEC and was approved by the local ethical commit-
tee (Progetto di Ricerca 2009/3).
At 8 weeks of age, ApoE−/− mice were fed ad libitum with 
a western type diet (21% fat, 0.15% cholesterol, and 19.5% 
casein; Harlan, Bresso, Italy) for 8 weeks. Then, SPG com-
plexes were administrated once a day, by intraperitoneal 
injection, for three consecutive days. The mice were eutha-
nized with an overdose of Avertin 2.5% (Sigma Aldrich, St 
Louis, MO), followed by cervical dislocation on the fourth 
day.8 The heart and the arterial tree were perfused with 
saline solution under physiological pressure. The LOX-1 
mRNA and protein expression in the aorta (from the last part 
of the ascending up to the thoracic aorta) was analyzed by 
quantitative reverse transcription-PCR and by western blot.
Each mouse was weighed before and after treatments, and 
there was no significant change in total body weight in any of 
the groups. We observed a significant downregulation of LOX-1 
mRNA and protein in the aorta of mice treated with 0.05 mg/
kg SPG/Olr1AS (Figure 2a–c). In particular, we found a 63% 
reduction in the LOX-1 protein level in aortas of mice treated 
with SPG/Olr1AS compared with phosphate-buffered saline 
and CTRL (Figure 2b). Neither phosphate-buffered saline nor 
a scramble ODN SPG complex (SPG/CTRL) had any effect on 
LOX-1 expression (Figure 2a–c). Interestingly, we also observed 
a significant decrease in LOX-1 mRNA and protein at a lower 
dosage of SPG/Olr1AS (0.005 mg/kg)  (Figure 2d–f). However, 
at this concentration of SPG/Olr1AS complex, the LOX-1 pro-
tein level in the mice aortas was decreased by 32% compared 
with controls (Figure 2f). To assess the possible proinflamma-
tory effect of SPG complex both in vitro and in vivo, we also 
investigated tumor necrosis factor-α and nuclear factor-κB 
expression in RAW 264.7 cells and aortic tissues. Consistent 
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with Takedatsu et al.,1 we did not observe any increase in these 
proinflammatory molecules (data not shown). Furthermore, no 
significant differences in mean triacylglycerol level, total choles-
terol, and cholesterol fractions were observed in the different 
treatment groups. This result was not unexpected because we 
used an acute treatment.
In summary, our data indicate that the inhibition of LOX-1 
can be beneficial in atherosclerotic disease. Moreover, this 
study exploits a novel delivery system for antisense ODNs 
with good in vivo efficacy at very low concentrations. The effi-
cacy of low SPG complex concentrations, as shown by our 
study, was confirmed by in vivo experiments using  SPG/
migration inhibitory factor complex at 0.007–0.0007 mg/kg 
body weight (Y. Koyama, personal communication).
These data suggest that humans, like mice, will benefit 
from lowering LOX-1 activity. Thus, SPG should be consid-
ered as an innovative and useful delivery system to reduce 
the inflammation process in atherosclerosis and cardio-
vascular diseases.
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Figure 1 loX-1 downregulation in rAW 264.7 cells. The incubation of RAW264.7 cells with SPG/ASOlr1 (25 nmol/l) for 24 hours decreased 
the basal expression of LOX-1 mRNA and protein, as determined by (a) qRT-PCR and (b) western blot analysis. LOX-1 mRNA and protein 
levels were normalized to the level of β-actin. (c) The data are expressed as relative optical density compared with β-actin from three separate 
experiments with duplicate samples. *P < 0.05, **P < 0.01, ***P < 0.005. AU, arbitrary unit; CTRL, scramble control oligonucleotide; PBS, 
phosphate-buffered saline; qRT-PCR, quantitative reverse transcription-PCR; SPG, Schizophyllan.
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Figure 2 loX-1 downregulation in Apoe−/− mice. The effects of the two different dosages of SPG/Olr1AS on the expression of (a,d) LOX-1 
mRNA and (b,c,e,f) protein in ApoE−/− aortas. β-Actin was used as the loading control. Representative images from three mouse aortas are 
shown (in b,e). *P < 0.05, **P < 0.01. ApoE, apolipoprotein E; AU, arbitrary unit; CTRL, scramble control oligonucleotide; PBS, phosphate-
buffered saline; SPG, Schizophyllan.
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